154 related articles for article (PubMed ID: 17212641)
21. Sustained virologic response with short-course ribavirin and peginterferon treatment in 2 patients coinfected with HIV and HCV genotype 1.
Patel MR; Mullen MP; Dieterich DT
AIDS Read; 2006 Mar; 16(3):164, 168-9; discussion 168-9. PubMed ID: 16538956
[TBL] [Abstract][Full Text] [Related]
22. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
23. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
24. Effect of liver steatosis on therapeutic response in chronic hepatitis C virus genotype 1 infected patients in hungary.
Werling K; Schaff Z; Dinya E; Tulassay Z
Pathol Oncol Res; 2010 Jun; 16(2):149-57. PubMed ID: 19757200
[TBL] [Abstract][Full Text] [Related]
25. Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.
Hu KQ; Currie SL; Shen H; Cheung RC; Ho SB; Bini EJ; McCracken JD; Morgan T; Bräu N; Schmidt WN; Jeffers L; Wright TL;
Dig Dis Sci; 2007 Feb; 52(2):570-8. PubMed ID: 17226072
[TBL] [Abstract][Full Text] [Related]
26. [Metabolic syndrome in patients with chronic hepatitis C genotype 1].
Baĭzhanova ZhZh; Ignatova TM; Nekrasova TP; Abdurakhmanov DT
Vestn Ross Akad Med Nauk; 2011; (1):3-7. PubMed ID: 21400720
[TBL] [Abstract][Full Text] [Related]
27. Impact of steatosis on long-term histological outcome in chronic hepatitis C after antiviral therapy.
Hung CH; Kuo FY; Wang JH; Lu SN; Hu TH; Chen CH; Lee CM; Eng HL
Antivir Ther; 2006; 11(4):483-9. PubMed ID: 16856622
[TBL] [Abstract][Full Text] [Related]
28. HCV virological response during treatment of chronic hepatitis C is associated with liver histological improvement in patients with HCV/HIV co-infection.
Castro G; Ramalho LN; Zucoloto S; Martinelli Ade L; Figueiredo JF
Braz J Infect Dis; 2008 Jun; 12(3):180-5. PubMed ID: 18833400
[TBL] [Abstract][Full Text] [Related]
29. Association between hepatic steatosis and hepatic expression of genes involved in innate immunity in patients with chronic hepatitis C.
Toyoda H; Kumada T; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Kitabatake S; Murakami Y
Cytokine; 2013 Aug; 63(2):145-50. PubMed ID: 23673288
[TBL] [Abstract][Full Text] [Related]
30. HCV-specific T-cell response in relation to viral kinetics and treatment outcome (DITTO-HCV project).
Pilli M; Zerbini A; Penna A; Orlandini A; Lukasiewicz E; Pawlotsky JM; Zeuzem S; Schalm SW; von Wagner M; Germanidis G; Lurie Y; Esteban JI; Haagmans BL; Hezode C; Lagging M; Negro F; Homburger Y; Neumann AU; Ferrari C; Missale G;
Gastroenterology; 2007 Oct; 133(4):1132-43. PubMed ID: 17919489
[TBL] [Abstract][Full Text] [Related]
31. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.
Rubbia-Brandt L; Quadri R; Abid K; Giostra E; Malé PJ; Mentha G; Spahr L; Zarski JP; Borisch B; Hadengue A; Negro F
J Hepatol; 2000 Jul; 33(1):106-15. PubMed ID: 10905593
[TBL] [Abstract][Full Text] [Related]
32. Hepatic steatosis in chronic hepatitis C: impact on response to anti-viral treatment with peg-interferon and ribavirin.
Guidi M; Muratori P; Granito A; Muratori L; Pappas G; Lenzi M; Bianchi FB
Aliment Pharmacol Ther; 2005 Nov; 22(10):943-9. PubMed ID: 16268968
[TBL] [Abstract][Full Text] [Related]
33. Analysis of the sustained virological response in patients with chronic hepatitis C and liver steatosis.
Piccoli Lde Z; Mattos AA; Coral GP; Mattos AZ; Santos DE
Arq Gastroenterol; 2011; 48(3):179-85. PubMed ID: 21952702
[TBL] [Abstract][Full Text] [Related]
34. Improvement of steatosis after interferon therapy in HCV genotype 4 is related to weight loss.
Esmat G; El Akel W; Metwally M; Soliman A; Doss W; Hamid MA; Kamal M; Zalata K; Khattab H; El-Kassas M; Esmat M; Hasan A; El-Raziky M
Indian J Gastroenterol; 2009; 28(2):45-8. PubMed ID: 19696987
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy.
Testino G; Borro P
Hepatology; 2011 Apr; 53(4):1409-10. PubMed ID: 21190159
[No Abstract] [Full Text] [Related]
36. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
Lok AS; Everhart JE; Chung RT; Kim HY; Everson GT; Hoefs JC; Greenson JK; Sterling RK; Lindsay KL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Ghany MG; Morishima C;
Hepatology; 2009 Jun; 49(6):1828-37. PubMed ID: 19291787
[TBL] [Abstract][Full Text] [Related]
37. Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
Lok AS; Everhart JE; Chung RT; Padmanabhan L; Greenson JK; Shiffman ML; Everson GT; Lindsay KL; Bonkovsky HL; Di Bisceglie AM; Lee WM; Morgan TR; Ghany MG; Morishima C;
Clin Gastroenterol Hepatol; 2007 Feb; 5(2):245-54. PubMed ID: 17296533
[TBL] [Abstract][Full Text] [Related]
38. Optimizing treatment regimens in hepatitis C.
Darling JM; Fried MW
Clin Liver Dis; 2006 Nov; 10(4):835-50. PubMed ID: 17164120
[TBL] [Abstract][Full Text] [Related]
39. [HCV entry as a new therapeutic target in chronic hepatitis C].
Dabrowska MM; Panasiuk A; Flisiak R
Pol Merkur Lekarski; 2009 Aug; 27(158):140-3. PubMed ID: 19856882
[TBL] [Abstract][Full Text] [Related]
40. Association between PNPLA3[G]/I148M variant, steatosis and fibrosis stage in hepatitis C virus - genetic matters.
Crisan D; Grigorescu M; Crisan N; Craciun R; Lupsor M; Radu C; Grigorescu MD; Suciu A; Epure F; Avram L; Leach N
J Physiol Pharmacol; 2019 Aug; 70(4):. PubMed ID: 31642820
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
